Biogen Inc
NASDAQ: BIIB
$159.99
-$4.90 (-3.0%)
Closing Price on November 15, 2024
BIIB Articles
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the biotech...
Published:
Last Updated:
A new research report from the analysts at Cowen highlights the firm's top health care picks, many of which have some huge upside potential to the posted price targets.
Published:
Tuesday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include GE, Gilead Sciences, Oracle, Under Armour and El Pollo Loco.
Published:
One sector that could be poised to do well could be the biotech arena, and the team at RBC has five top stocks for investors to focus on as best ideas.
Published:
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or...
Published:
Last Updated:
24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to catch up to peers.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published:
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
Biogen Idec reported better-than-expected third-quarter results before the market opened Wednesday.
Published:
Cowen asked the analysts which stocks should be on their shopping lists. Here are the six with the biggest upside potential.
Published:
In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy right now.
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published: